

MGRC Healthcare and Innoquest Pathology on Strategic Collaboration on Genetic Screening Services Marketing

Tuesday, 15 October 2024 - MGRC Healthcare Sdn Bhd (“**MGRC-H**”), a wholly owned subsidiary of **Malaysian Genomics Resource Centre Berhad** (“**MGRC**” or “**the Group**”), a leading genomics and biopharmaceutical specialist, is partnering with Innoquest Pathology Sdn Bhd (“**Innoquest**”), the largest provider of laboratory services in Malaysia with the aim of procuring and marketing MGRC’s genetic screening services.



Encik Noor Azri bin Dato' Sri Noor Azerai, Executive Chairman of MGRC is delighted and anticipated a synergistic collaboration with Innoquest in expanding the presence of genetic screening services and products covering **Dtect, Origene and Origene with Pharmacogenomics (PGx)** screening methodology in the market at large in the future. This is part of MGRC’s vision to be the leader in **preventive medicine – incorporating both MGRC’s genomic and biopharmaceuticals (Cell & Gene Therapy) suite of products and services.**

In line with Innoquest’s vision to deliver better clinical insights through innovative diagnostic technology, this partnership with MGRC gives Innoquest access to MGRC’s genetic screening services and provide these to its network of healthcare providers throughout Malaysia which includes more than 200 hospitals and 5,000 clinics.

According to **Adam Hathsey, Innoquest’s Deputy CEO for West Malaysia**, these genetic screening provides insights to patients’ genetic make-up and help assess their potential risks and predisposition to certain diseases. This helps patients to be more aware in managing their lifestyle choices and in planning their regular health screening according to their individual risk factors.

ABOUT MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients.

For more information, please contact us via the following:

Website : www.mgrc.com.my
Email : enquiries@mgrc.com.my
Telephone No. : +6011 5880 4488

ABOUT INNOQUEST PATHOLOGY SDN BHD

Innoquest Pathology, born from the merger of Clinipath, Quantum, and Gribbles, is the largest private provider of diagnostic laboratory services in the country. Since our inception in 1996, we have grown to operate over 85 electronically-linked pathology facilities throughout Peninsular Malaysia, Sabah, and Sarawak. Headquartered in Petaling Jaya, we employ over 1,200 staff nationwide, performing over 4 million patient episodes per year. Supported by a deep bench of industry expertise and groundbreaking technology, Innoquest proudly serves clinicians, hospitals, medical centres, and their patients with advanced diagnostic testing methods. Our network offers a wide range of in-vitro diagnostic tests to help detect diseases and monitor health. As the only multidisciplinary clinical laboratory in Malaysia with dual accreditation from the College of American Pathologists (CAP) and MS ISO15189, we maintain best-in-class standards, services, and laboratory practices, aiming to strengthen our global presence as a centre of excellence in testing.

For more information, visit <https://innoquest.com.my> or follow our updates on LinkedIn, Facebook.

Contact Person:
Name : Matthew Mok
Designation : Head of Marketing
Telephone No.: +60 12-601 6386
Email: matthew.mok@innoquest.com.my